Pharma: Be Prepared For Tougher Price Negotiations For IO Combos And Expansions In Europe
Executive Summary
Payers are increasingly likely to implement new strategies to manage price negotiations for immuno-oncology combinations, as competition heats up among the drug class. Mechanisms allowing for the negotiation of different prices for combination therapies do not exist at present, but payers insist that new tools must emerge.